Education
About Us
Working with TipRanks
Follow Us
Xoma Corp (XOMA)
NASDAQ:XOMA
XOMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.35 - $35.23
Previous CloseN/A
Volume8.24K
Average Volume (3M)43.84K
Market Cap
$392.49M
Enterprise Value$498.29M
Total Cash (Recent Filing)$83.94M
Total Debt (Recent Filing)$114.58M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 06, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.44
Shares Outstanding12,087,719
10 Day Avg. Volume63,629
30 Day Avg. Volume43,841
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue12.92
Enterprise Value/Gross Profit13.33
Enterprise Value/Ebitda-1.63K
Forecast
1Y Price Target
$68.50Price Target Upside110.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Acquisitions And Portfolio ExpansionXOMA announced two important transactions, further expanding its broad portfolio, which includes acquisitions that provide important non-dilutive capital.
Financial PerformanceRecent revenue beat estimates significantly, showing strong financial performance.
Royalty Revenue PotentialXOMA's acquisition of LAVA Therapeutics adds royalties on two Phase I, pharma-sponsored T cell engager assets to the portfolio.
Bears Say
Market CompetitionThe combination of high unmet need, inclusion of U.S. patients following the FDA’s removal of the U.S. hold, and the strong efficacy from Phase 2 makes this a higher-impact opportunity for XOMA’s near-term royalty revenue growth, but also presents competitive challenges.
Risk And Development StagesXOMA is strategically positioned with a diversified portfolio of royalty-bearing assets across various indications, each with unique stages of development and risk profiles.
Xoma News
XOMA FAQ
What was Xoma Corp’s price range in the past 12 months?
Xoma Corp lowest stock price was $18.35 and its highest was $35.23 in the past 12 months.
What is Xoma Corp’s market cap?
Xoma Corp’s market cap is $392.49M.
When is Xoma Corp’s upcoming earnings report date?
Xoma Corp’s upcoming earnings report date is Nov 06, 2025 which is in 67 days.
How were Xoma Corp’s earnings last quarter?
Xoma Corp released its earnings results on Aug 13, 2025. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of -$0.15 by $0.59.
Is Xoma Corp overvalued?
According to Wall Street analysts Xoma Corp’s price is currently Undervalued.
Does Xoma Corp pay dividends?
Xoma Corp does not currently pay dividends.
What is Xoma Corp’s EPS estimate?
Xoma Corp’s EPS estimate is -0.04.
How many shares outstanding does Xoma Corp have?
Xoma Corp has 12,087,719 shares outstanding.
What happened to Xoma Corp’s price movement after its last earnings report?
Xoma Corp reported an EPS of $0.44 in its last earnings report, beating expectations of -$0.15. Following the earnings report the stock price went up 8.538%.
Which hedge fund is a major shareholder of Xoma Corp?
Currently, no hedge funds are holding shares in XOMA
Xoma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$68.50 (110.96% Upside)
$68.50 (110.96% Upside)
Hedge Fund Trend
Increased
By 11.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $50.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.06%
12-Months-Change
Fundamentals
Return on Equity
-12.42%
Trailing 12-Months
Asset Growth
-8.15%
Trailing 12-Months
Company Description
Xoma Corp
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
XOMA Stock 12 Month Forecast
Average Price Target
$68.50
▲(110.96% Upside)
Technical Analysis
Ownership Overview
12.16% Insiders
15.42% Mutual Funds
29.69% Other Institutional Investors
35.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---